Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Levocetirizine dihydrochloride
Drug ID BADD_D01273
Description Levocetirizine is a selective histamine H1 antagonist used to treat a variety of allergic symptoms.[A181748,A181790,L7694] It is the R enantiomer of [cetirizine].[L7694] Levocetirizine has greater affinity for the histamine H1 receptor than cetirizine.[L7694] Levocetirizine was granted FDA approval in 1995.[L7694]
Indications and Usage Levocetirizine is indicated to treat symptoms of perennial allergic rhinitis and uncomplicated skin manifestations of chronic idiopathic urticaria.[L7694] It is also used over the counter for a variety of mild allergy symptoms.[A181748]
Marketing Status approved
ATC Code R06AE09
DrugBank ID DB06282
KEGG ID D08118
MeSH ID C472067
PubChem ID 9955977
TTD Drug ID D0M8PW
NDC Product Code 72789-023; 49574-632; 66039-837; 51655-148; 55910-241; 63187-663; 0363-5528; 0536-1144; 51927-5050; 62991-3149; 11822-0241; 21130-732; 0093-7701; 33342-200; 46122-531; 0363-2241; 69367-238; 70518-2797; 71205-476; 71309-112; 43598-735; 11822-5252; 41163-938; 0363-5529; 69230-321; 62135-917; 68788-7699; 71335-0940; 72559-007; 17511-106; 49574-521; 51552-1415; 31722-551; 31722-659; 41167-3510; 41167-3535; 42571-312; 51655-564; 51672-4161; 70000-0362; 70934-835; 71205-204; 71335-0789; 43579-006; 52562-300; 43063-479; 43598-810; 0363-3901; 63868-473; 68462-346; 71205-988; 71335-0418; 62207-009; 36800-241; 37808-126; 68071-2836; 68788-7934; 71335-1305; 72288-241; 73581-201; 43579-005; 65372-1161; 41250-488; 42571-122; 45802-680; 63187-922; 63629-8500; 71335-1952; 10135-639; 28877-5801; 55111-045; 66022-0108; 11673-847; 0113-0241; 41167-3530; 49035-492; 55111-282; 63629-2533; 69842-761; 70518-3366; 71205-210; 76168-501; 28877-0090; 42765-008; 53104-7644; 30142-717; 42543-712; 50228-136
UNII SOD6A38AGA
Synonyms levocetirizine | levocetrizine | acetic acid, (2-(4-((R)-(4-chlorophenyl)phenylmethyl)-1-piperazinyl)ethoxy)- | (2-(4-((R)-p-chloro-alpha-phenylbenzyl)-1-piperazinyl)ethoxy)acetic acid | levocetirizine hydrochloride | Xusal | levocetirizine dihydrochloride | (2-(4-((R)-(4-chlorophenyl)phenylmethyl)piperazin-1-yl)ethoxy)acetic acid dihydrochloride | cetirizine (R)-form dihydrochloride | acetic acid, (2-(4-((R)-(4-chlorophenyl)phenylmethyl)-1-piperazinyl)ethoxy)-, dihydrochloride | Xyzal | UCB-28556
Chemical Information
Molecular Formula C21H27Cl3N2O3
CAS Registry Number 130018-87-0
SMILES C1CN(CCN1CCOCC(=O)O)C(C2=CC=CC=C2)C3=CC=C(C=C3)Cl.Cl.Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Aggression19.05.01.001---
Agitation17.02.05.012; 19.06.02.001--
Anaphylactic reaction10.01.07.001; 24.06.03.006--
Angioedema10.01.05.009; 22.04.02.008; 23.04.01.001---
Asthenia08.01.01.001---
Cholestasis09.01.01.001---
Cough22.02.03.001--
Depression19.15.01.001--
Dizziness02.11.04.006; 17.02.05.003; 24.06.02.007--
Dry mouth07.06.01.002--
Dysgeusia07.14.03.001; 17.02.07.003--
Dyskinesia17.01.02.006--
Dyspnoea02.11.05.003; 22.02.01.004--
Dysuria20.02.02.002--
Epistaxis22.04.03.001; 24.07.01.005--
Fatigue08.01.01.002--
Glomerulonephritis10.02.01.006; 20.05.01.001---
Hallucination19.10.04.003--
Hepatitis09.01.07.004---
Hypersensitivity10.01.03.003--
Hypotension24.06.03.002--
Increased appetite08.01.09.027; 14.03.01.003---
Insomnia17.15.03.002; 19.02.01.002--
Myalgia15.05.02.001--
Nasopharyngitis11.01.13.002; 22.07.03.002---
Nausea07.01.07.001--
Oedema08.01.07.006; 14.05.06.010---
Palpitations02.11.04.012--
Paraesthesia17.02.06.005; 23.03.03.094--
Pharyngitis07.05.07.004; 11.01.13.003; 22.07.03.004--
The 1th Page    1 2    Next   Last    Total 2 Pages